Intellia TherapeuticsNTLA
Price$12.12Intrinsic value$33.24174% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $33.24median of 2 methodsbased on filings through 30 Jun 2026
Market Price $12.12Price as of 1 Oct 2026
Margin of Safety +174.3%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 29.3%/yr (balance of the path).24.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 627.5%Yr 725.6%Yr 823.7%Yr 921.9%Yr 1020.0%
29.3% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 11.8%
Volatility vs market (adjusted beta)1.53

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetIntellia TherapeuticsNTLAHealth Care
Valuation
P/E—
P/S28.9×
P/B2.2×
EV / Revenue27.1×
EV / EBITDA—
Profitability
Gross margin—
Operating margin-711.7%
Net margin-672.2%
FCF margin-586.0%
Returns
ROE-55.0%
ROA-46.7%
ROIC—
Growth
Revenue growth (YoY)2.8%
5-yr fwd EPS growth24.0%
Financial strength
Debt / Equity—
Current ratio6.65×
Altman Z-Score2.8
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.